News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Speedel Pharmaceuticals, Inc. Begins Phase IIa Trial With Next Generation Renin Inhibitor



10/31/2006 5:05:31 PM

BASEL, Switzerland and BRIDGEWATER, N.J., Oct. 31, 2006 (PRIMEZONE) -- Speedel (SWX:SPPN) announces that it has reached another significant milestone in the development of its family of renin inhibitors with the start of a Phase IIa clinical trial with SPP635 for the treatment of hypertension. This compound is the first of a next generation of renin inhibitors following Speedel's lead product SPP100 (aliskiren, Tekturna(1)), which is partnered with Novartis and awaiting marketing approval from the FDA and the EMEA(2). SPP635 is the most advanced compound in the SPP600 series and is one of several new proprietary renin inhibitors invented by Speedel Experimenta, the company's late-stage research unit.

Read at Prime Zone


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES